What Octagon Capital Advisors LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1839435 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 3M |
| +20.9% |
| $138.8M |
| 12.5% |
ABVXAbivax S.A. | 993K | +46.7% | $132.3M | 11.9% |
COGTCogent Biosciences, Inc. | 2.4M | ±0% | $90.9M | 8.2% |
ALMSAlumis Inc. | 2.8M | ±0% | $79.7M | 7.2% |
AVBPArriVent BioPharma, Inc. | 2M | ±0% | $68.5M | 6.2% |
TSHATaysha Gene Therapies, Inc. | 9.7M | +9.4% | $66M | 5.9% |
BIOABioAge Labs, Inc. | 1.7M | ±0% | $42.8M | 3.9% |
MIRMMirum Pharmaceuticals, Inc. | 338.9K | ±0% | $39.7M | 3.6% |
KYMRKymera Therapeutics, Inc. | 310K | −27.1% | $35.5M | 3.2% |
AKTSAktis Oncology, Inc. | 960.8K | ±0% | $31M | 2.8% |
XENEXenon Pharmaceuticals Inc. | 490K | ±0% | $29.6M | 2.7% |
ERASCA INCCALLCall option | 1.3M | New | $23M | 2.1% |
PALIPalisade Bio, Inc. | 10.3M | ±0% | $21.5M | 1.9% |
OCULOcular Therapeutix, Inc | 2.1M | −34.5% | $20.4M | 1.8% |
IRONDisc Medicine, Inc. | 270K | ±0% | $19.7M | 1.8% |
SMMTSummit Therapeutics Inc. | 1.3M | New | $18.2M | 1.6% |
PHVSPharvaris N.V. | 456.7K | +176.8% | $15.8M | 1.4% |
ANLAdlai Nortye Group Ltd. | 934.7K | New | $10.7M | 1% |
DTILPrecision Biosciences Inc | 1.4M | −39.6% | $10.6M | 1% |
DBVTDBV Technologies S.A. | 574.2K | ±0% | $9.4M | 0.8% |
FTHFaeth Therapeutics, Inc. | 361K | New | $9M | 0.8% |
GYREGyre Therapeutics, Inc. | 954.4K | New | $6.3M | 0.6% |
TRVITrevi Therapeutics, Inc. | 315K | −78.8% | $5.9M | 0.5% |
UNCYUnicycive Therapeutics, Inc. | 1M | ±0% | $4.7M | 0.4% |
CNTXContext Therapeutics Inc. | 3.1M | −41.9% | $1.7M | 0.2% |
GOSSGossamer Bio, Inc. | 7.8M | ±0% | $1.3M | 0.1% |
